Experimental cancer drug PTX-100 enters early human testing

NCT ID NCT03900442

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five days every two weeks, for up to four cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PTX-100

What this could lead to

If successful, this could point toward a new treatment option for certain advanced cancers that have not responded to standard therapies.

What could go wrong

This is a very early Phase 1 trial with only 25 participants, so it is too small to prove effectiveness. The drug may not work or could cause significant side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer diffuse gastric cancer malignant pancreatic neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Epworth Healthcare

    Melbourne, Victoria, 3002, Australia